Redeye returns with an updated view following Nekkar’s Q1 figures that was surprisingly soft even if volatility should be expected. We cut mainly H1’25 figures while expecting a recovery in H2’25. The tender pipeline continued to grow, and a few deals could easily offset our current estimates. Despite the quarterly volatility, the fundamentals continue to strengthen, supporting our positive long-term view.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/